{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:55:04Z","timestamp":1785542104008,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":174,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.crphar.2022.100116","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:43:07Z","timestamp":1656466987000},"page":"100116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Metabolic and clinical effect of alpha-lipoic acid administration in schizophrenic subjects stabilized with atypical antipsychotics: A 12-week, open-label, uncontrolled study"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-6560","authenticated-orcid":false,"given":"Fiammetta","family":"Iannuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo Antonio","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Campolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crphar.2022.100116_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1100\/2012\/509838","article-title":"Alfa-lipoic acid controls tumor growth and modulates hepatic redox state in ehrlich-ascites-carcinoma-bearing mice","author":"Al Abdan","year":"2012","journal-title":"Sci. World J."},{"issue":"9491","key":"10.1016\/j.crphar.2022.100116_bib2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2014a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.crphar.2022.100116_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11883-009-0016-8","article-title":"The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials","volume":"11","author":"Alsheikh-Ali","year":"2009","journal-title":"Curr. Atherosclerosis Rep."},{"issue":"2","key":"10.1016\/j.crphar.2022.100116_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, torsades de Pointes, and psychotropic medications: a 5-year update","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"issue":"1","key":"10.1016\/j.crphar.2022.100116_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","article-title":"Hyperprolactin\u00e9mies induites par les antipsychotiques : physiopathologie, clinique et surveillance","volume":"40","author":"Besnard","year":"2014","journal-title":"L\u2019Enc\u00e9phale"},{"issue":"1","key":"10.1016\/j.crphar.2022.100116_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40291-013-0017-8","article-title":"Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy","volume":"17","author":"Burghardt","year":"2013","journal-title":"Mol. Diagn. Ther."},{"issue":"2","key":"10.1016\/j.crphar.2022.100116_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1194\/jlr.M026948","article-title":"Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro","volume":"54","author":"Canfr\u00e1n-Duque","year":"2013","journal-title":"JLR (J. Lipid Res.)"},{"issue":"3","key":"10.1016\/j.crphar.2022.100116_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.crphar.2022.100116_bib9","first-page":"15","article-title":"Metabolic issues and cardiovascular disease in patients with psychiatric disorders","volume":"118","author":"Casey","year":"2005","journal-title":"Am. J. Med. Suppl."},{"key":"10.1016\/j.crphar.2022.100116_bib10","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"1","key":"10.1016\/j.crphar.2022.100116_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatr."},{"issue":"19","key":"10.1016\/j.crphar.2022.100116_bib12","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.crphar.2022.100116_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2011.00069","article-title":"Diabetes and alpha lipoic acid","volume":"2","author":"Golbidi","year":"2011","journal-title":"Front. Pharmacol."},{"issue":"20","key":"10.1016\/j.crphar.2022.100116_bib14","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.crphar.2022.100116_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","author":"Hirsch","year":"2017","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.crphar.2022.100116_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/oby.20966","article-title":"Effects of \u03b1-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss","volume":"23","author":"Huerta","year":"2015","journal-title":"Obesity"},{"issue":"12","key":"10.1016\/j.crphar.2022.100116_bib17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.crphar.2022.100116_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.crphar.2022.100116_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0b013e31816777f7","article-title":"A\u00a0preliminary investigation of \u03b1-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia","volume":"28","author":"Kim","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.crphar.2022.100116_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/YIC.0000000000000132","article-title":"Adjunctive \u03b1-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics","volume":"31","author":"Kim","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.crphar.2022.100116_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.crphar.2022.100116_bib22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/cen.13303","article-title":"Effects of oral \u03b1-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial","volume":"86","author":"Li","year":"2017","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"10.1016\/j.crphar.2022.100116_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/0253-7176.119471","article-title":"Metabolic syndrome in schizophrenia","volume":"35","author":"Malhotra","year":"2013","journal-title":"Indian J. Psychol. Med."},{"issue":"5","key":"10.1016\/j.crphar.2022.100116_bib24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metabol. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.crphar.2022.100116_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatr."},{"issue":"2","key":"10.1016\/j.crphar.2022.100116_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-2007-12210","article-title":"Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in alzheimer disease patient fibroblasts","volume":"12","author":"Moreira","year":"2007","journal-title":"J.\u00a0Alzheim. Dis."},{"issue":"2_Suppl. l","key":"10.1016\/j.crphar.2022.100116_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","article-title":"Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia","volume":"22","author":"O\u2019Keane","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"1","key":"10.1016\/j.crphar.2022.100116_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0269881107077815","article-title":"Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents","volume":"22","author":"Ojala","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"10","key":"10.1016\/j.crphar.2022.100116_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0899-9007(01)00658-X","article-title":"Molecular aspects of lipoic acid in the prevention of diabetes complications","volume":"17","author":"Packer","year":"2001","journal-title":"Nutrition"},{"key":"10.1016\/j.crphar.2022.100116_bib30","doi-asserted-by":"crossref","DOI":"10.3238\/arztebl.2014.0069","article-title":"The treatment of type 2 diabetes","author":"Pfeiffer","year":"2014","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"10.1016\/j.crphar.2022.100116_bib31","article-title":"Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alphalipoic acid: a randomized double-blinded placebocontrolled study","author":"Porasuphatana","year":"2012","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"10.1016\/j.crphar.2022.100116_bib32","author":"Premi"},{"issue":"3","key":"10.1016\/j.crphar.2022.100116_bib33","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2007.01.003","article-title":"Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus","volume":"120","author":"Rader","year":"2007","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.crphar.2022.100116_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment \u2013 pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacology & Therapeutics"},{"issue":"8","key":"10.1016\/j.crphar.2022.100116_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/biom9080356","article-title":"Insights on the use of \u03b1-lipoic acid for therapeutic purposes","volume":"9","author":"Salehi","year":"2019","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.crphar.2022.100116_bib36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/JCP.0000000000000800","article-title":"\u03b1-Lipoic acid as adjunctive treatment for schizophrenia","volume":"37","author":"Sanders","year":"2017","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.crphar.2022.100116_bib37","first-page":"1","article-title":"Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the world federation of societies of biological Psychiatry (WFSBP) and Canadian network for mood and anxiety treatments (CANMAT) taskforce","author":"Sarris","year":"2022","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.crphar.2022.100116_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pnpbp.2016.06.012","article-title":"Dysregulation of hypothalamic modulation in olanzapine treated male rats","volume":"71","author":"Sezlev-Bilecen","year":"2016","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"issue":"10","key":"10.1016\/j.crphar.2022.100116_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.bbagen.2009.07.026","article-title":"Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential","volume":"1790","author":"Shay","year":"2009","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"3","key":"10.1016\/j.crphar.2022.100116_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"Tse","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.crphar.2022.100116_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jmf.2016.0070","article-title":"Effects of alpha-lipoic acid supplementation on plasma adiponectin levels and some metabolic risk factors in patients with schizophrenia","volume":"20","author":"Vidovi\u0107","year":"2017","journal-title":"J.\u00a0Med. Food"},{"issue":"2\u20133","key":"10.1016\/j.crphar.2022.100116_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2014.08.021","article-title":"A\u00a0randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism","volume":"159","author":"Vincenzi","year":"2014","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.crphar.2022.100116_bib43","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.111.189456","article-title":"Acute reversal of endothelial dysfunction in the elderly after antioxidant consumption","volume":"59","author":"Wray","year":"2012","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.crphar.2022.100116_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2007.05.007","article-title":"Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells","volume":"56","author":"Yang","year":"2007","journal-title":"Pharmacol. Res."},{"issue":"3\u20134","key":"10.1016\/j.crphar.2022.100116_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lfs.2009.11.009","article-title":"Lipoic acid effects on established atherosclerosis","volume":"86","author":"Ying","year":"2010","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.crphar.2022.100116_bib46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/CIRCULATIONAHA.107.725275","article-title":"Dietary \u03b1-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E\u2013deficient and apolipoprotein E\/Low-Density lipoprotein receptor\u2013deficient mice","volume":"117","author":"Zhang","year":"2008","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1016\/j.crphar.2025.100215","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257122000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257122000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:29:12Z","timestamp":1719620952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257122000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":46,"alternative-id":["S2590257122000360"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2022.100116","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.crphar.2025.100215","asserted-by":"object"}]},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic and clinical effect of alpha-lipoic acid administration in schizophrenic subjects stabilized with atypical antipsychotics: A 12-week, open-label, uncontrolled study","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2022.100116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100116"}}